Posted by Michael Wonder on 06 Jun 2025
Sydnexis announces European Commission approval of SYD-101, the first and only pharmaceutical treatment for slowing the progression of paediatric myopia
5 June 2025 - Exclusive licensing partner Santen will commercialise SYD-101 under the brand name Ryjunea in the EU.
Sydnexis today announced that the European Commission has granted marketing authorisation for SYD-101, the company’s proprietary low dose atropine formulation, for slowing the progression of paediatric myopia.
